Gastric Cancer | Clinical

Frontline Bemarituzumab Doublet Prolongs Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

January 16, 2021

In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.

Janjigian Reviews the Evolving Role of Anti-HER2 Agents in Advanced Gastric Cancer

October 05, 2020

In an interview with Targeted Oncology following a virtual presentation for the ISGIO 2020, Yelena Janjigian, MD, provided an overview of the role of HER2-targeted therapies in advanced gastric cancer. She also explained the importance of biomarker testing in this space.

FDA Grants Fast Track Designation to DKN-01 in Gastric/GEJ Adenocarcinoma

September 24, 2020

The FDA has granted a Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express the protein DKK1, following disease progression on or after prior treatment with fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, human epidermal receptor growth factor/neu-targeted therapy.

Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers

September 21, 2020

In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.

Nivolumab/Ipilimumab Improves Survival Outcomes in Metastatic Gastric/GEJ Cancers

August 11, 2020

Overall survival and progression-free survival were improved with nivolumab plus ipilimumab and chemotherapy compared with chemotherapy alone as frontline treatment of patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.